Prader-Willi Syndrome
New Prader-Willi syndrome research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), evidence on medicines for hyperphagia (a persistent, hard-to-control drive to eat) became clearer: DCCR showed short-term controlled benefit with worsening after stopping, while phase 3 carbetocin was negative. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Medicines for hyperphagia. DCCR had supportive results, while carbetocin did not show benefit in a large trial.
- GLP-1 and incretin drugs. Small real-world reports suggested hunger scores may improve even when weight change is unclear.
- Sleeve surgery outcomes. Longer follow-up showed that some weight regain can happen after early surgical weight loss.
- Behavior and sleep programs. Some programs reported short-term changes in daily functioning along with metabolic measures.
- Sleep and breathing risks. Reports added detail on which sleep measurements lined up with risk signals in specific groups.
New
September 2026
- Hunger symptoms. Semaglutide was linked to lower hunger scores; weight change was unclear.
- Inpatient behavior care. After inpatient stabilization, aggressive incidents were reported less often.
- Spine fusion outcomes. Spinal fusion corrected scoliosis curves, with complications also reported.
August 2026
- Growth hormone timing. Underweight children showed early lean-tissue catch-up over time.
- Infant feeding issues. Feeding and growth problems were common in early infancy.
- Breathing during sleep. Low breathing during sleep was linked to pulmonary hypertension in one study.
- Mosaic testing needs. Some mosaic cases may need testing beyond a blood sample.
July 2026
- Hunger medicine trial. Carbetocin nasal spray did not lower hunger scores versus placebo.
- Bowel problems. Constipation and stool accidents were common in one clinic sample.
- Executive function. Many children had planning, self-control, and memory difficulties.
June 2026
- Infant sleep support. Extra oxygen lowered central breathing pauses during an overnight sleep test.
- Muscle measurement. Calf ultrasound results were similar to scan-based muscle mass estimates.
- Caregiver burden link. Surveys linked loneliness with higher reported caregiver burden.
May 2026
- DCCR and hunger control. In reports of DCCR (Vykat XR), hunger symptoms were more controlled for some people while treatment was continued.
- Monitor fluid and blood sugar. Fluid retention (edema) and high blood sugar remained key issues to monitor with DCCR.
- Sleeve surgery: weight loss over years. After sleeve gastrectomy in PWS, weight loss was greatest in the first 1–2 years and was only partly maintained by year 5.
- Waist size and health measures. In clinic-based data, waist size continued to track with blood pressure and lab measures in PWS.
April 2026
- Sensory processing and irritability. In one dataset, day-to-day sensory processing differences closely tracked irritability levels.
- Noisy breathing during growth hormone. One case report linked noisy breathing during growth hormone therapy to upper-airway swelling in a person with a complex airway history.
- Confirming parent-of-origin in MAGEL2. Long-read genetic testing confirmed that a MAGEL2 variant was on the paternal copy of the gene in reported cases.
- Early biology signals from computer analysis. An exploratory computer analysis highlighted glycosylation and early brain-development regulators as repeatedly flagged pathways in PWS model data.
March 2026
- Gut-targeted hunger drug (not studied in PWS). A gut-acting drug lowered hunger ratings in adults with obesity, but it has not been tested in people with Prader-Willi syndrome.
- ADHD stimulant and food-seeking (single case). In one reported child with Prader-Willi syndrome, a long-acting ADHD stimulant was linked to fewer food-seeking episodes.
- Puberty: start vs later hormone levels. In Prader-Willi syndrome, puberty often begins, but low sex hormone levels are common later on.
- Sleep apnea monitoring during growth hormone. Some children developed new sleep apnea while receiving growth hormone, supporting the need for ongoing sleep-breathing monitoring.
February 2026
- Oxytocin and feeding measures. In infants given oxytocin, swallowing imaging improved more often, but one feeding score did not differ from placebo.
- Sleep breathing differences. Sleep studies reported a wider mix of breathing event types and lower oxygen levels than typical obstructive sleep apnea, supporting the need for careful sleep monitoring in Prader-Willi syndrome.
- When diagnosis happens. Reports suggested Prader-Willi syndrome is often diagnosed after birth, and normal prenatal screening did not rule out some genetic causes in case reports.
January 2026
- Hunger and weight (DCCR). Over 16 weeks, continuing DCCR was linked to less worsening in hunger scores and less weight gain than placebo, with similar side-effect rates between groups.
- Sleep apnea and growth hormone. In this dataset, older children had more severe obstructive sleep apnea before starting growth hormone, and new sleep apnea after starting occurred at similar rates across age groups.
- Calorie and nutrient intake. In adolescents and adults with Prader-Willi syndrome, reported calorie intake averaged well above recommended targets, with higher saturated fat and sodium and lower calcium, iron, and magnesium.
- More than one genetic cause. One case report described a child with Prader-Willi syndrome who also had a separate inherited cause of severe hearing loss, showing that symptoms can sometimes have more than one diagnosis.
Get the monthly update by email
Subscribe here to receive an email when a new monthly Prader-Willi syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).